not tagged
dizal pharmaceuticals,bayer
['nsclc', 'sclc', 'bayer', 'dizal']
an #esmo22 scooplet for ya boy: after posting encouraging phase 2 data, dizal is planning to launch a phase 3 study of its treatment for nsclc patients with exon20 insertion mutations in the u.s. before year's end. 
staff writer @FierceBiotech covering new drug development | ?? mbayer@questex.com or DM for Signal | past: @CBSNews | he/him